NCT02118285View on ClinicalTrials.gov

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 28, 2014

Primary Completion Date

November 12, 2015

Study Completion Date

November 12, 2015

Conditions
Ovarian CancerFallopian Tube CarcinomaPrimary Peritoneal Carcinoma
Interventions
DRUG

Fludarabine

Fludarabine 25 mg/m\^2 IV on days -6 through -2 from NK cell infusion

DRUG

Cyclophosphamide

Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion

BIOLOGICAL

NK cells

CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0

BIOLOGICAL

IL-2

IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion

DRUG

INCB024360

INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)

Trial Locations (1)

55455

University of Minnesota Masonic Cancer Center, Minneapolis

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER